Junzhong Lin, Jianhong Peng, and Yixin Zhao have contributed equally to this work.
Oligometastatic disease can potentially be cured when an optimal approach is performed. Early recurrence after liver resection is an intractable problem, and the clinical implications remain unknown in colorectal liver oligometastases (CLOM) patients. This study aimed to investigate the clinical characteristics, risk factors, and prognosis related to early recurrence in these patients.
A total of 307 consecutive patients with CLOM undergoing curative liver resection were retrospectively reviewed between September 1999 and June 2016. Early recurrence was defined as any recurrence or death from CLOM that occurred within 6 months of liver resection.
With a median follow-up time of 31.7 months, the 3-year overall survival (OS) and recurrence-free survival rates were 68.7 and 42.5%, respectively. Forty-nine (16.0%) patients developed early recurrence and showed a poorer 3-year OS than those with non-early recurrence (22.3 vs. 75.8%, P < 0.001) or later recurrence (22.3 vs. 52.8 vs. 63.2%, P < 0.001). Moreover, early recurrence was identified as an independent predictor of 3-year OS [hazard ratio (HR) 6.282; 95% confidence interval (CI) 3.980–9.915, P < 0.001]. In multivariate analysis, a node-positive primary tumor [odds ratio (OR) 2.316; 95% CI 1.097–4.892, P = 0.028) and metastatic diameter > 3 cm (OR 2.560; 95% CI 1.290–5.078; P = 0.007) were shown to be risk factors for early recurrence. The salvage liver resection rate for patients with early recurrence was significantly lower than that for patients with later recurrence (4.1 vs. 19.7%, P = 0.010).
Early recurrence should be investigated in routine clinical practice, even in patients with CLOM after curative liver resection. Detailed preoperative comprehensive measurements might help stratify high-risk patients, and a non-surgical treatment for early recurrence might represent an effective alternative.
Chafai N, Chan CL, Bokey EL, Dent OF, Sinclair G, Chapuis PH (2005) What factors influence survival in patients with unresected synchronous liver metastases after resection of colorectal cancer? Colorectal Dis 7(2):176–181. https://doi.org/10.1111/j.1463-1318.2004.00744.xCrossRefPubMed
Cucchetti A, Ferrero A, Cescon M, Donadon M, Russolillo N, Ercolani G, Stacchini G, Mazzotti F, Torzilli G, Pinna AD (2015) Cure model survival analysis after hepatic resection for colorectal liver metastases. Ann Surg Oncol 22(6):1908–1914. https://doi.org/10.1245/s10434-014-4234-0CrossRefPubMed
Engels B, Gevaert T, Everaert H, De Coninck P, Sermeus A, Christian N, Storme G, Verellen D, De Ridder M (2012) Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer. Radiat Oncol 7:34. https://doi.org/10.1186/1748-717X-7-34CrossRefPubMedPubMedCentral
Folprecht G, Gruenberger T, Bechstein W, Raab HR, Weitz J, Lordick F, Hartmann JT, Stoehlmacher-Williams J, Lang H, Trarbach T, Liersch T, Ockert D, Jaeger D, Steger U, Suedhoff T, Rentsch A, Kohne CH (2014) Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study). Ann Oncol 25(5):1018–1025. https://doi.org/10.1093/annonc/mdu088CrossRefPubMed
Imai K, Allard MA, Benitez CC, Vibert E, Sa CA, Cherqui D, Castaing D, Bismuth H, Baba H, Adam R (2016) Early recurrence after hepatectomy for colorectal liver metastases: what optimal definition and what predictive factors? Oncologist 21(7):887–894. https://doi.org/10.1634/theoncologist.2015-0468CrossRefPubMedPubMedCentral
Jung SW, Kim DS, Yu YD, Han JH, Suh SO (2016) Risk factors for cancer recurrence or death within 6 months after liver resection in patients with colorectal cancer liver metastasis. Ann Surg Treat Res 90(5):257–264. https://doi.org/10.4174/astr.2016.90.5.257CrossRefPubMedPubMedCentral
Kanas GP, Taylor A, Primrose JN, Langeberg WJ, Kelsh MA, Mowat FS, Alexander DD, Choti MA, Poston G (2012) Survival after liver resection in metastatic colorectal cancer: review and meta-analysis of prognostic factors. Clin Epidemiol 4:283–301. https://doi.org/10.2147/CLEP.S34285PubMedPubMedCentral
Lan YT, Chang SC, Yang SH, Lin CC, Wang HS, Jiang JK, Chen WS, Lin TC, Chiou SH, Lin JK (2014) Comparison of clinicopathological characteristics and prognosis between early and late recurrence after curative surgery for colorectal cancer. Am J Surg 207(6):922–930. https://doi.org/10.1016/j.amjsurg.2013.08.035CrossRefPubMed
Leung U, Gonen M, Allen PJ, Kingham TP, DeMatteo RP, Jarnagin WR, D’Angelica MI (2016) Colorectal cancer liver metastases and concurrent extrahepatic disease treated with resection. Ann Surg. https://doi.org/10.1097/SLA.0000000000001624PubMedCentral
Li S, He N, Li W, Wu PH (2014) Debulking treatment with CT-guided percutaneous radiofrequency ablation and hepatic artery infusion of floxuridine improves survival of patients with unresectable pulmonary and hepatic metastases of colorectal cancer. Chin J Cancer 33(6):295–305. https://doi.org/10.5732/cjc.013.10191CrossRefPubMedPubMedCentral
Malik HZ, Gomez D, Wong V, Al-Mukthar A, Toogood GJ, Lodge JP, Prasad KR (2007) Predictors of early disease recurrence following hepatic resection for colorectal cancer metastasis. Eur J Surg Oncol 33(8):1003–1009. https://doi.org/10.1016/j.ejso.2007.01.005CrossRefPubMed
Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Praet M, Bethe U, Van Cutsem E, Scheithauer W, Gruenberger T (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016. https://doi.org/10.1016/S0140-6736(08)60455-9CrossRefPubMedPubMedCentral
Otto G, Duber C, Hoppe-Lotichius M, Konig J, Heise M, Pitton MB (2010) Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 251(5):796–803. https://doi.org/10.1097/SLA.0b013e3181bc9faeCrossRefPubMed
Sasaki K, Morioka D, Conci S, Margonis GA, Sawada Y, Ruzzenente A, Kumamoto T, Iacono C, Andreatos N, Guglielmi A, Endo I, Pawlik TM (2016) The tumor burden score: a new, “Metro-ticket” prognostic tool for colorectal liver metastases based on tumor size and number of tumors. Ann Surg. https://doi.org/10.1097/SLA.0000000000002064
Takeda A, Sanuki N, Tsurugai Y, Oku Y, Aoki Y (2016) Stereotactic body radiotherapy for patients with oligometastases from colorectal cancer: risk-adapted dose prescription with a maximum dose of 83–100 Gy in five fractions. J Radiat Res 57(4):400–405. https://doi.org/10.1093/jrr/rrw029CrossRefPubMedPubMedCentral
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, Aranda AE, Bardelli A, Benson A, Bodoky G, Ciardiello F, D’Hoore A, Diaz-Rubio E, Douillard JY, Ducreux M, Falcone A, Grothey A, Gruenberger T, Haustermans K, Heinemann V, Hoff P, Kohne CH, Labianca R, Laurent-Puig P, Ma B, Maughan T, Muro K, Normanno N, Osterlund P, Oyen WJ, Papamichael D, Pentheroudakis G, Pfeiffer P, Price TJ, Punt C, Ricke J, Roth A, Salazar R, Scheithauer W, Schmoll HJ, Tabernero J, Taieb J, Tejpar S, Wasan H, Yoshino T, Zaanan A, Arnold D (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386–1422. https://doi.org/10.1093/annonc/mdw235CrossRefPubMed
Van den Begin R, Engels B, Gevaert T, Duchateau M, Tournel K, Verellen D, Storme G, De Ridder M (2014) Impact of inadequate respiratory motion management in SBRT for oligometastatic colorectal cancer. Radiother Oncol 113(2):235–239. https://doi.org/10.1016/j.radonc.2014.11.005CrossRefPubMed
Vigano L, Capussotti L, Lapointe R, Barroso E, Hubert C, Giuliante F, Ijzermans JN, Mirza DF, Elias D, Adam R (2014) Early recurrence after liver resection for colorectal metastases: risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6025 patients. Ann Surg Oncol 21(4):1276–1286. https://doi.org/10.1245/s10434-013-3421-8CrossRefPubMed
Weiser MR, Jarnagin WR, Saltz LB (2013) Colorectal cancer patients with oligometastatic liver disease: what is the optimal approach? Oncology 27(11):1074–1078 PubMed
Zhang S, Gao F, Luo J, Yang J (2010) Prognostic factors in survival of colorectal cancer patients with synchronous liver metastasis. Colorectal Dis 12(8):754–761. https://doi.org/10.1111/j.1463-1318.2009.01911.xCrossRefPubMed
- Early recurrence in patients undergoing curative resection of colorectal liver oligometastases: identification of its clinical characteristics, risk factors, and prognosis
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II